For people facing early-stage triple-negative breast cancer, finding the right treatment path is vital. New data from a review of several large trials shows that adding an immune checkpoint inhibitor to chemotherapy can improve the chances of achieving a pathological complete response. This means the treatment helps clear more of the cancer from the body before surgery.
The study looked at over 3,000 patients. The results showed this combination worked better than chemotherapy alone, regardless of whether the tumors were positive or negative for a specific protein called PD-L1. While the extra medicine helped more patients reach that goal, it did come with a trade-off: these drugs caused more immune-related side effects compared to standard chemotherapy.
One important finding is that testing for PD-L1 levels alone might not be enough to decide if a patient should receive this specific treatment. While the results are promising for improving outcomes in triple-negative breast cancer, the increased risk of immune-related toxicity means patients and doctors must weigh the benefits carefully.
